Establishment of a COVID-19 mRNA vaccine technological innovation transfer hub to scale up world-wide manufacturing

WHO and its associates are trying to find to develop the potential of small- and middle-income nations around the world (LMICs) to produce COVID-19 vaccines and scale up manufacturing to enhance world entry to these essential equipment to convey the pandemic underneath control.

WHO will aid the establishment of 1 (or much more, as suitable) engineering transfer1 hub(s) that will  use a hub and spoke product (REF) to transfer a in depth technological innovation offer and give suitable education to interested producers in LMICs. This initiative will initially prioritize the mRNA-vaccine engineering2 but could broaden to other systems in the future.

The intention is for these hubs to help the establishment of production course of action at an industrial or semi-industrial level permitting teaching and provision of all required normal operating techniques for creation and good quality handle. It is important that the know-how used is either absolutely free of mental assets constraints in LMICs, or that this kind of rights are manufactured out there to the know-how hub and the potential recipients of the technological innovation by means of non-special licenses to deliver, export and distribute the COVID-19 vaccine in LMICs, which include by the COVAX facility. Preference will be specified to candidates who have now created scientific data in human beings, as this sort of clinical details will lead to accelerated approval of the vaccines in LMICs.

It is expected that WHO will operate with funders and donors to mobilize economic support to create the hubs and, as they are currently being recognized, to help the transfer of technological know-how to selected companies in LMICs, getting into thought the need to have to build everlasting vaccine output capability in locations where this is at the moment mostly absent. This broader objective will guarantee that all WHO regions will be capable to deliver vaccines as essential preparedness actions versus potential infectious threats.

To help this exercise, we are searching for expressions of interest from:

  1. Small/middle-sized (public or non-public) companies of health care goods (medicine, vaccines or drug substances) preferably, but not completely, in LMICs, which could host a COVID-19 mRNA hub and:
    • Assemble the engineering up to superior manufacturing methods-grade pilot a lot for clinical trials
    • Transfer the correct know-how and technologies to present or new makers in LMICs to permit them to produce and develop COVID-19 mRNA vaccines
  2. Entrepreneurs (community or personal) of know-how and/or intellectual home rights. These may perhaps be tutorial institutions, pharmaceutical providers, non-governmental companies or any other entity prepared to contribute these to a technological know-how transfer hub, below the auspices of WHO, to enable production of mRNA-based COVID-19 vaccines in LMICs.

For this initial expression of fascination, entities eager to be deemed as a technologies transfer hub (as briefly described over less than 1) or able to provide the essential know-how, process teaching, and mental assets rights (as briefly described previously mentioned underneath 2), are invited to present a quick summary of their capacity, and their desire in taking part in the institution of a COVID-19 vaccine technological know-how transfer hub to:

Martin Friede ([email protected]) and Raj Lengthy ([email protected])

A phone for fascination from companies in LMICs fascinated in getting the technological innovation formulated by the technological know-how transfer hub(s) will be issued by WHO in the coming weeks. Desire will be given to makers of medicines, vaccines or lively pharmaceutical substances centered in LMICs and capable of manufacturing clinical solutions on a big scale under Superior Manufacturing Techniques. Yet another critical issue taken into consideration will be prospect for sustainability and experience with WHO Prequalification.


Technology transfer hubs have been supported earlier by WHO to permit the prosperous improvement and transfer of processes for adjuvant manufacturing and for influenza vaccine output (ref).

The factors why WHO decided to advance promptly on mRNA vaccines are as follows:

  • They have proven extremely efficacious in preserving from COVID-19, and defense is taken care of to a massive degree in opposition to variants
  • This know-how is pretty flexible and lets rather fast adaptation of the vaccine to variants, if wanted
  • They can be developed by makers of medicines and health-related lively substances in addition to vaccines
  • Several specialized characteristics are free of charge of Mental Home Legal rights in a lot of nations of the planet.


Amelia J. Bell

Next Post

What inflation is and how it impacts you

Tue May 18 , 2021
Americans’ anticipations for inflation over the following several decades also hit its maximum degree in practically a decade, in accordance to a further report by the Federal Reserve Lender of New York.   General, the expectation is that the inflation rate will be up to 3.4% 1 12 months from […]